Answer: The fall in your white cell count due to Rituximab is usually mild and not very significant. If you do have another relapse, we would recommend that you participate in one of the clinical trials of new agents, including; Moxetumomab, Veramufenib, or Ibrutinib. These studies will be open in several centers including MD Anderson Cancer Center in Houston, The Ohio State University in Columbus, The National Institutes of Health in Bethesda, and Memorial Sloan Kettering in New York.
Hopefully, one of these centers are close enough to you to be able to take advantage of these new agents. These can be offered in the form of pills, and have a high expectation of being effective and relatively non-toxic. If you’re not able to travel to these locations, your doctor can try concomitant Pentostatin plus Rituxan. As always please consult with your doctor and if you have further questions.
Posted May 2013 in the category: Multiple Relapses